JP2017526706A5 - - Google Patents

Download PDF

Info

Publication number
JP2017526706A5
JP2017526706A5 JP2017513199A JP2017513199A JP2017526706A5 JP 2017526706 A5 JP2017526706 A5 JP 2017526706A5 JP 2017513199 A JP2017513199 A JP 2017513199A JP 2017513199 A JP2017513199 A JP 2017513199A JP 2017526706 A5 JP2017526706 A5 JP 2017526706A5
Authority
JP
Japan
Prior art keywords
alkyl
cancer
tumor
cell
lymphoma
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
JP2017513199A
Other languages
English (en)
Japanese (ja)
Other versions
JP2017526706A (ja
Filing date
Publication date
Application filed filed Critical
Priority claimed from PCT/US2015/049213 external-priority patent/WO2016040498A1/en
Publication of JP2017526706A publication Critical patent/JP2017526706A/ja
Publication of JP2017526706A5 publication Critical patent/JP2017526706A5/ja
Pending legal-status Critical Current

Links

JP2017513199A 2014-09-10 2015-09-09 イソオキサゾールカルボキサミド化合物 Pending JP2017526706A (ja)

Applications Claiming Priority (5)

Application Number Priority Date Filing Date Title
US201462048759P 2014-09-10 2014-09-10
US62/048,759 2014-09-10
US201562146794P 2015-04-13 2015-04-13
US62/146,794 2015-04-13
PCT/US2015/049213 WO2016040498A1 (en) 2014-09-10 2015-09-09 Isoxazole carboxamide compounds

Publications (2)

Publication Number Publication Date
JP2017526706A JP2017526706A (ja) 2017-09-14
JP2017526706A5 true JP2017526706A5 (enExample) 2018-10-18

Family

ID=55459522

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2017513199A Pending JP2017526706A (ja) 2014-09-10 2015-09-09 イソオキサゾールカルボキサミド化合物

Country Status (6)

Country Link
US (2) US10428029B2 (enExample)
EP (1) EP3193603A4 (enExample)
JP (1) JP2017526706A (enExample)
AU (1) AU2015315167A1 (enExample)
CA (1) CA2960274A1 (enExample)
WO (1) WO2016040498A1 (enExample)

Families Citing this family (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
BR112017004589A2 (pt) 2014-09-10 2018-01-23 Epizyme Inc composto, composição farmacêutica, método para tratar um paciente, uso de um composto, kit, e método para tratar um distúrbio mediado por proteína smyd
AU2015315174B2 (en) 2014-09-10 2019-12-12 Epizyme, Inc. Smyd inhibitors
WO2016040511A1 (en) 2014-09-10 2016-03-17 Epizyme, Inc. Isoxazole carboxamides as irreversible smyd inhibitors
EP3190891B1 (en) 2014-09-10 2020-01-15 Epizyme, Inc. Isoxazolecarboxamide substituted by a cyclohexylamine as smyd protein inhibitors
WO2016204006A1 (ja) 2015-06-17 2016-12-22 住友化学株式会社 有害節足動物防除剤
CR20210148A (es) * 2018-09-21 2021-05-18 Novartis Ag Compuestos de isoxazol carboxamida y usos de los mismos
CN109879868B (zh) * 2019-03-07 2022-04-22 南通大学 含2-芳基噁唑结构的吡唑酰胺类化合物的制备和应用

Family Cites Families (24)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US3065225A (en) * 1960-02-05 1962-11-20 Hoffmann La Roche N', n4-di-isoxazolylcarbonyl-sulfanilamide derivatives
DE19930075A1 (de) * 1999-06-30 2001-01-04 Bayer Ag Neue Amino- und Amidosulfonamide als antivirale Mittel
GB0017518D0 (en) * 2000-07-17 2000-08-30 Merck Sharp & Dohme Therapeutic agents
EP1390034A4 (en) * 2001-04-03 2005-07-13 Merck & Co Inc N-SUBSTITUTED NONARYL HETEROCYCLO AMIDYL-NMDA / NR2B ANTAGONISTS
CA2449249A1 (en) * 2001-06-12 2002-12-19 Merck & Co., Inc. Nr2b receptor antagonists for the treatment or prevention of migraines
DE10306250A1 (de) * 2003-02-14 2004-09-09 Aventis Pharma Deutschland Gmbh Substituierte N-Arylheterozyklen, Verfahren zu ihrer Herstellung und ihre Verwendung als Arzneimittel
WO2005004810A2 (en) * 2003-07-02 2005-01-20 Merck & Co., Inc. Arylsulfonamide derivatives
US7709645B2 (en) * 2004-07-27 2010-05-04 Sgx Pharmaceuticals, Inc. Pyrrolo-pyridine kinase modulators
TW200634003A (en) * 2004-12-22 2006-10-01 Astrazeneca Ab Chemical compounds
US7291743B2 (en) * 2005-03-29 2007-11-06 Geneblue Corporation Isoxazole derivatives and methods of treating nitric oxide mediated diseases
NL2000284C2 (nl) 2005-11-04 2007-09-28 Pfizer Ltd Pyrazine-derivaten.
CN101563082A (zh) * 2006-09-05 2009-10-21 窦德献 治疗免疫介导性皮肤病的组合物和方法
EA015952B1 (ru) * 2007-05-03 2011-12-30 Пфайзер Лимитед 2-пиридинкарбоксамидные производные в качестве модуляторов натриевых каналов
WO2008137834A2 (en) 2007-05-04 2008-11-13 Osi Pharmaceuticals, Inc. Crystal structure of smyd3 protein
EP2528925B1 (en) * 2010-01-29 2017-07-05 Hanmi Science Co., Ltd. THIENO[3,2-d]PYRIMIDINE DERIVATIVES HAVING INHIBITORY ACTIVITY ON PROTEIN KINASES
WO2013043826A1 (en) * 2011-09-21 2013-03-28 Abbvie Inc. Tricyclic compounds useful as protein kinase inhibitors
CA2895509C (en) * 2012-12-18 2021-08-17 Alcyone Lifesciences, Inc. Systems and methods for reducing or preventing backflow in a delivery system
JP2016512825A (ja) * 2013-03-15 2016-05-09 シファ・バイオメディカル・コーポレイションShifa Biomedical Corporation 抗プロタンパク質転換酵素サブチリシン/ケキシン9型(抗pcsk9)化合物および心血管疾患の治療および/または予防におけるその使用方法
WO2016040511A1 (en) 2014-09-10 2016-03-17 Epizyme, Inc. Isoxazole carboxamides as irreversible smyd inhibitors
EP3190891B1 (en) 2014-09-10 2020-01-15 Epizyme, Inc. Isoxazolecarboxamide substituted by a cyclohexylamine as smyd protein inhibitors
JP2017527577A (ja) * 2014-09-10 2017-09-21 エピザイム,インコーポレイティド 置換ピロリジン化合物
AU2015315174B2 (en) 2014-09-10 2019-12-12 Epizyme, Inc. Smyd inhibitors
BR112017004589A2 (pt) 2014-09-10 2018-01-23 Epizyme Inc composto, composição farmacêutica, método para tratar um paciente, uso de um composto, kit, e método para tratar um distúrbio mediado por proteína smyd
EP3193609A4 (en) 2014-09-10 2018-02-28 Epizyme, Inc. Substituted pyrrolidine carboxamide compounds

Similar Documents

Publication Publication Date Title
JP2017528464A5 (enExample)
JP2016514695A5 (enExample)
JP2017527577A5 (enExample)
JP2017528460A5 (enExample)
JP2017538659A5 (enExample)
JP2019514950A5 (enExample)
CN106660974A (zh) 含氨磺酰基的1,2,5‑噁二唑类衍生物、其制备方法及其在医药上的应用
JP2017527576A5 (enExample)
RU2014112345A (ru) Хинолил-содержащее соединение гидроксамовой кислоты, способ его получения, фармацевтическая композиция, содержащая это соединение, и его применение
JP2020515571A5 (enExample)
JP2017510641A5 (enExample)
CY1118730T1 (el) Παραγωγα πυριδινης ως αναστολεις της αναδιαταχθεισας κατα την διαρκεια διαλοιμωξης (ret) κινασης
JP2013064024A5 (enExample)
IL272697B2 (en) A polymorphic form of TG02
NZ595602A (en) Anti-cancer drugs, and uses relating for malignant melanoma and other cancers
RU2014101626A (ru) Полиморфы 2-амид 1-({4-метил-5-[2-(2, 2, 2-трифтор-1, 1-диметил-этил)-пиридин-4-ил]тиазол-2-ил}амида) (s)-пирролидин-1, 2-дикарбоновой кислоты
JP2017528461A5 (enExample)
CN1791396A (zh) 组蛋白脱乙酰基酶抑制剂与化疗剂的组合
JP2020506884A5 (enExample)
JP2013528215A5 (enExample)
RU2017124371A (ru) Комбинация производного 6-оксо-1,6-дигидро-пиридазина, обладающего противораковой активностью, с производным хиназолина
JP2016106092A (ja) 組合せ
HK1259409A1 (zh) 酪蛋白激酶1δ在乳腺癌中的治疗靶向
TN2010000139A1 (en) Organic compounds
JP2023515687A5 (enExample)